Clinical Trial Update: Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes [EARLY_Phase 1]

View source ↗

Summary

Early-phase trial update for anti-NY ESO-1 mTCR peripheral blood lymphocytes in HLA-A2 positive metastatic cancers; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Neoplasm
• Malignant Neoplasm of Brain

Drugs mentioned

• Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes (anti-NY ESO-1 mTCR PBMC)

Snippet

Sponsor: Albert Einstein College of Medicine | Conditions: HLA-A2 Positive Cells Present, Metastatic Malignant Neoplasm | EARLY_Phase 1 | Status: TERMINATED | Results posted: 2023-08-04